KR101363120B1 - 항-인터페론 알파 모노클로날 항체 및 사용 방법 - Google Patents

항-인터페론 알파 모노클로날 항체 및 사용 방법 Download PDF

Info

Publication number
KR101363120B1
KR101363120B1 KR1020077020583A KR20077020583A KR101363120B1 KR 101363120 B1 KR101363120 B1 KR 101363120B1 KR 1020077020583 A KR1020077020583 A KR 1020077020583A KR 20077020583 A KR20077020583 A KR 20077020583A KR 101363120 B1 KR101363120 B1 KR 101363120B1
Authority
KR
South Korea
Prior art keywords
delete delete
antibody
ifnα
antibodies
aco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077020583A
Other languages
English (en)
Korean (ko)
Other versions
KR20070107753A (ko
Inventor
쟈끄 반쉐로
킬리 프릴리만
버지니아 파스쿠알
안나 캐롤리나 팰루카
Original Assignee
베일러 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베일러 리서치 인스티튜트 filed Critical 베일러 리서치 인스티튜트
Publication of KR20070107753A publication Critical patent/KR20070107753A/ko
Application granted granted Critical
Publication of KR101363120B1 publication Critical patent/KR101363120B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077020583A 2005-02-10 2006-02-09 항-인터페론 알파 모노클로날 항체 및 사용 방법 Expired - Fee Related KR101363120B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65223305P 2005-02-10 2005-02-10
US60/652,233 2005-02-10
PCT/US2006/004643 WO2006086586A2 (en) 2005-02-10 2006-02-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (2)

Publication Number Publication Date
KR20070107753A KR20070107753A (ko) 2007-11-07
KR101363120B1 true KR101363120B1 (ko) 2014-02-13

Family

ID=36694481

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077020583A Expired - Fee Related KR101363120B1 (ko) 2005-02-10 2006-02-09 항-인터페론 알파 모노클로날 항체 및 사용 방법

Country Status (14)

Country Link
US (2) US8080638B2 (https=)
EP (1) EP1851248B1 (https=)
JP (2) JP5837730B2 (https=)
KR (1) KR101363120B1 (https=)
CN (1) CN101155831B (https=)
AU (1) AU2006213800B2 (https=)
BR (1) BRPI0607490A2 (https=)
CA (1) CA2597265C (https=)
IL (1) IL184808A0 (https=)
MX (1) MX2007009466A (https=)
NO (1) NO343054B1 (https=)
RU (1) RU2431638C2 (https=)
WO (1) WO2006086586A2 (https=)
ZA (1) ZA200706425B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056654A (zh) * 2004-10-07 2007-10-17 苏黎士大学 用于预防和治疗银屑病的i型干扰素阻断剂
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CN101155831B (zh) 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
JP5230022B2 (ja) * 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
CN101678100A (zh) * 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
US8426170B2 (en) 2007-01-25 2013-04-23 Universite Libre De Bruxelles Method for evaluating the response of an individual to a treatment with a type I interferon (IFN)
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
CA2686861A1 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2254998B1 (en) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
BRPI0823046B1 (pt) * 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
CN101580546B (zh) * 2009-06-04 2011-09-14 中国疾病预防控制中心病毒病预防控制所 人源抗人干扰素α抗体及其应用
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
AU2013204776A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20150128849A (ko) 2013-03-15 2015-11-18 얀센 바이오테크 인코포레이티드 인터페론 알파 및 오메가 항체 길항제
JP6742237B2 (ja) * 2013-07-03 2020-08-19 イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ ヒト抗ｉｆｎ−アルファ抗体
EP3083946B1 (en) * 2013-12-16 2024-08-07 The University of North Carolina at Chapel Hill Depletion of plasmacytoid dendritic cells
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EP3302561A4 (en) 2015-06-08 2019-02-06 Debiopharm International SA COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
KR102766022B1 (ko) 2015-08-28 2025-02-10 데비오팜 인터네셔날 에스 에이 Cd37 의 검출을 위한 항체 및 검정
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
CN107858449A (zh) * 2017-12-05 2018-03-30 安徽九川生物科技有限公司 一种犬干扰素α生物学活性检测方法
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
US12144818B2 (en) 2018-05-30 2024-11-19 Debiopharm International, S.A. Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
JP2022527542A (ja) 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法
RU2748953C1 (ru) * 2019-12-30 2021-06-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Рекомбинантный Fab-scFv на основе нейтрализующего антитела против интерферона бета-1а человека и антитела против рецептора ErbB2 человека
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
SI4126066T1 (sl) * 2020-03-27 2026-04-30 Avidity Biosciences, Inc. Sestavki in postopki zdravljenja mišične distrofije
CN119841955A (zh) * 2023-12-19 2025-04-18 重庆艾生斯生物工程有限公司 一种抗MxA抗体或其功能性片段及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3001687C2 (de) 1980-01-18 1981-09-17 Kläger, Karlheinz, 8901 Neusäß Verstellbare Düse an einem handbetätigten Flüssigkeitszerstäuber
US4423147A (en) 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4605394A (en) 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4824432A (en) 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4362155A (en) 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
DE3211263A1 (de) 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
AU2844889A (en) 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
ES2133285T3 (es) 1991-04-17 1999-09-16 Medisup Int Nv Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
DK0601052T3 (da) 1991-08-30 1996-11-18 Genentech Inc Terapeutisk fremgangsmåde til behandling af IDDM
DE69324671D1 (de) 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
WO1998006431A2 (en) 1996-08-16 1998-02-19 Osther Kurt B Method for treating diabetes
US5804955A (en) * 1996-10-30 1998-09-08 Cherry Semiconductor Corporation Low voltage current limit circuit with temperature insensitive foldback network
US20030018174A1 (en) 1997-10-06 2003-01-23 Genentech, Inc. Monoclonal antibodies to IFNAR2
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
CN1454215B (zh) 1999-11-15 2013-01-02 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US6660523B2 (en) 2000-09-21 2003-12-09 Schering Corporation Dendritic cells; methods
EP1351707B9 (en) 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
WO2004003211A1 (en) 2002-06-26 2004-01-08 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2007525458A (ja) 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
CN101056654A (zh) 2004-10-07 2007-10-17 苏黎士大学 用于预防和治疗银屑病的i型干扰素阻断剂
CN101155831B (zh) 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5230022B2 (ja) 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J INTERFERON AND CYTOKINE RESEARCH 1999 19:319-326 *

Also Published As

Publication number Publication date
US8333965B2 (en) 2012-12-18
AU2006213800A1 (en) 2006-08-17
ZA200706425B (en) 2014-07-30
MX2007009466A (es) 2007-12-07
NO343054B1 (no) 2018-10-22
KR20070107753A (ko) 2007-11-07
US8080638B2 (en) 2011-12-20
CA2597265C (en) 2015-03-24
CN101155831A (zh) 2008-04-02
RU2007133608A (ru) 2009-03-20
EP1851248A2 (en) 2007-11-07
CN101155831B (zh) 2015-08-19
AU2006213800B2 (en) 2012-02-09
IL184808A0 (en) 2007-12-03
BRPI0607490A2 (pt) 2009-09-08
NO20074512L (no) 2007-10-31
US20080160030A1 (en) 2008-07-03
JP5837730B2 (ja) 2015-12-24
CA2597265A1 (en) 2006-08-17
JP2008529529A (ja) 2008-08-07
EP1851248B1 (en) 2016-08-10
JP2014111644A (ja) 2014-06-19
WO2006086586A3 (en) 2006-10-12
WO2006086586A2 (en) 2006-08-17
RU2431638C2 (ru) 2011-10-20
US20120020963A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
KR101363120B1 (ko) 항-인터페론 알파 모노클로날 항체 및 사용 방법
JP5230022B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP7285936B2 (ja) Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
KR101754433B1 (ko) 항-ｃｄ100 항체 및 이의 사용 방법
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
KR100872210B1 (ko) 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
JP2018511322A (ja) イヌインターロイキン４受容体アルファに対する抗体
KR20150061041A (ko) 인간 ｏｘ４０ 수용체에 대한 결합 분자
JP7727632B2 (ja) イヌインターロイキン－４受容体α抗体
KR20080105111A (ko) 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
US7888481B2 (en) Anti-interferon alpha monoclonal antibodies and methods for use
CN109219616B (zh) Gm-csf抗体及其用途
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
TW201840585A (zh) 用於白斑病的治療的抗人cxcr3抗體
US20150166655A1 (en) Anti-interferon alpha monoclonal antibodies and methods of use
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
HK40003556B (en) Anti-gm-csf antibodies and uses thereof
EA041171B1 (ru) Антитела к рецептору онкостатина m и их применение
HK1105420B (en) Interferon alpha receptor 1 antibodies and their uses

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170131

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180129

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190124

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20200129

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240208

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240208